分化簇155（CD155）是一種單次跨膜的細胞表面蛋白，在正常組織中表達量很少或不表達，但在包括胰腺癌、膽管癌、結(jié)直腸癌、非小細胞肺癌、膀胱癌、乳腺癌的多種惡性腫瘤中高表達，使其能夠成為抗腫瘤藥物的理想靶點。CD155作為細胞黏附分子參與腫瘤細胞的黏附、遷移和極化，還作為免疫調(diào)節(jié)分子與T細胞或NK細胞上的包括TIGIT、DNAM-1、CD96的共刺激或共抑制受體相互作用，發(fā)揮免疫調(diào)節(jié)作用，影響免疫微環(huán)境。目前靶向CD155及其受體的藥物研發(fā)火熱，其高親和力受體TITIG有多種藥物進入III期臨床，直接靶向CD155及其受體DNAM-1和CD96的腫瘤治療也逐漸增加。通過對靶向CD155及其受體的藥物研究進展進行綜述，以期為后續(xù)的藥物研發(fā)提供依據(jù)。

Cluster of differentiation 155 (CD155) is a single-pass transmembrane cell surface protein with little or no expression in normal tissues, but in pancreatic cancer, cholangiocarcinoma, colorectal cancer, non-small cell lung cancer, bladder cancer and breast cancer. It is highly expressed in various malignant tumors of breast cancer, which makes it as an ideal target for anti-tumor drugs. As a cell adhesion molecule, CD155 participates in the adhesion, migration, and polarization of tumor cells. It also acts as an immunoregulatory molecule and interacts with costimulatory or costinhibitory receptors on T cells or NK cells, including TIGIT, DNAM-1, and CD96, which regulates and affects the immune microenvironment. At present, the research and development of drugs targeting CD155 and its receptors is hot, and its high-affinity receptor TITIG has a variety of drugs entering Phase III clinical trials, and tumor treatments that directly target CD155 and its receptors DNAM-1 and CD96 are also gradually increasing. This article reviews research progress of drugs targeting CD155 and its receptors, in order to provide a basis for subsequent drug development.

R966

湖北省科技支撐計劃項目（2015BCA316）